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colorectal cancer mortality was concentrated in the poor-
est quintile compared to the richest quintile. Weights larger 
than 4 did not increase the slope of the disparities trend.
Conclusions There is consistent evidence for a significant 
crossover in colorectal cancer disparity from 1980 to 2010. 
Trends in disparity can be accurately and readily summa-
rized using the HD*Calc tool. The disparity trend, com-
bined with published information on the timing of screen-
ing and treatment uptake, is concordant with the idea that 
introduction of medical screening and treatment leads to 
lower uptake in lower compared to higher SES populations 
and that differential uptake yields disparity in population 
mortality.
Keywords Disparities · Colorectal Cancer Mortality · 
HD*Calc · SES Quintiles · Concentration Index · 
Inequality Aversion Parameter
Introduction
Colon and rectum cancer (hereafter colorectal cancer) is the 
second most common cause of cancer death in the United 
States [1]. Survival rates are much higher for early than for 
late stage disease [2]. Between 1975 and 2010, mortality 
rates from colorectal cancer in the United States for white 
males dropped from 35 to less than 20 per 100,000 pop-
ulation [3]. This striking drop in mortality over just three 
decades represents an astonishing accomplishment. In 
this study, we evaluate whether the reduction in colorectal 
cancer death rates was equally distributed throughout the 
population.
Summary measures combine information on mortality 
or other health outcomes to represent the distribution of 
population health in a single numerical index. To explore 
Abstract 
Purpose Colorectal cancer mortality rates dropped by 
half in the past three decades, but these gains were accom-
panied by striking differences in colorectal cancer mortality 
by socioeconomic status (SES). Our research objective is to 
examine disparities in colorectal cancer mortality by SES, 
using a scientifically rigorous and reproducible approach 
with publicly available online tools, HD*Calc and NCI 
SES Quintiles.
Methods All reported colorectal cancer deaths in the 
United States from 1980 to 2010 were categorized into NCI 
SES quintiles and assessed at the county level. Joinpoint 
was used to test for significant changes in trends. Absolute 
and relative concentration indices (CI) were computed with 
HD*Calc to graph change in disparity over time.
Results Disparities by SES significantly declined until 
1993–1995, and then increased until 2010, due to a mor-
tality drop in populations living in high SES areas that 
exceeded the mortality drop in lower SES areas. HD*Calc 
results were consistent for both absolute and relative con-
centration indices. Inequality aversion parameter weights 
of 2, 4, 6 and 8 were compared to explore how much 
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the social distribution of the decline in mortality over time, 
we use new tools developed at the National Cancer Institute 
(NCI) at the National Institutes of Health: the Health Dis-
parities Calculator (HD*Calc) and the NCI Socioeconomic 
Status (SES) index. HD*Calc addresses the recommenda-
tion of an NCI monograph that multiple summary meas-
ures should be used to accurately evaluate trends in dis-
parities [4]. The recommendation to use multiple measures 
resulted after examination of the performance and suitabil-
ity of 23 summary measures of disparity. NCI developed 
the Health Disparities Calculator (HD*Calc) to create 
efficiencies in computations and graphing. HD*Calc is an 
online tool that calculates and graphs 11 summary dispar-
ity measures previously published in peer-reviewed jour-
nals [5]. The HD*Calc measures were selected from among 
those reviewed in the NCI monograph for their reliability 
and versatility.
Many dimensions of health disparity exist in the United 
States. Important differences in health outcome in popula-
tions’ signal disparity, and it is important to recognize the 
impact that social determinants have on health outcomes. 
Race, ethnicity, sex, sexual identity, age, disability, socio-
economic status, and geographic location all contribute to 
the ability to achieve good health and describe groups that 
have been historically subjected to discrimination or other 
social injustices [6]. Other studies have shown disparities 
in colorectal cancer mortality by race/ethnicity [7, 8]. We 
analyze disparities using HD*Calc by area socioeconomic 
status by linking mortality data to recently developed NCI 
SES quintiles.
The NCI SES quintiles are characterized by a standard 
set of factors. A standard set of factors reduces measure-
ment error and improves precision over time. The quintiles 
are linked at the smallest ecological unit available (which, 
for mortality, is Census tract), quintiles are calculated for 
each year using the same factors, and changes in trends in 
quintiles are assessed for significance. The NCI SES quin-
tiles, based on Census data that can be linked to individual 
data at the county or tract level, provide a consistent meas-
ure of SES [9]. SES is a key health determinant, and the 
previous analyses have shown large differences in cancer 
outcomes associated with SES over time [10–13].
In this study, we evaluate disparities in colorectal can-
cer mortality by SES using a set of summary indices, one 
relative and one absolute. We examine age-adjusted mor-
tality by county SES from 1980 to 2010 for the United 
States. While annual rates show a mortality decline for all 
groups and an apparent crossover of mortality rates among 
SES groups, we cannot draw scientific conclusions without 
estimating measures of disparity and assessing their pre-
cision. Thus, we use HD*Calc and the NCI SES quintiles 
[2] to address two research questions. First, how large was 
the disparity in colorectal cancer mortality rates by SES 
group? Second, did SES disparities change direction over 
time? The indices we use are sensitive to the direction of 
the SES gradient and include an inequality aversion param-
eter which can be adjusted to specify how much weight to 
give to each socioeconomic group.
Materials and methods
Data
Colorectal cancer mortality data collected by the National 
Vital Statistics System and accessed through the NCI’s 
SEER program and Census data for the United States from 
1980 to 2010 were combined at the county level; county 
is the smallest unit for which mortality data are released. 
Colorectal cancer mortality by SES was calculated for each 
NCI SES quintile for each year under study. Factor anal-
yses were used to derive the NCI SES index scores from 
seven county attributes: educational attainment of persons 
aged 25 and over, median household income, median gross 
rent, median value (dollars) for owner-occupied housing 
units, percent of persons under 150% poverty level among 
population, percent unemployed among the civilian popula-
tion aged 16 and over, and percent working class among the 
civilian employed population aged 16 years and over. These 
attributes were normalized using the rank transformation. 
The first factor that explained more than 80% of common 
variance was extracted for the index. SES quintiles were 
then formed from the index with equal populations within 
each quintile for each year.
Specifically, data from the 1980, 1990, and 2000 decen-
nial Census long form surveys and the American Commu-
nity Survey 5-year estimates (2005–2009, 2006–2010, and 
2007–2011) were used to construct the indices. For Cen-
sus years, we used the Census data. For intercensual years 
(1981–1989, 1991–1999, and 2001–2006), linear interpo-
lated SES scores from the two adjacent Census years were 
used. For the years that coincide with the middle years of 
the ACS 5-year estimates (2007, 2007, and 2008), the ACS 
data were used. For 2010, linear extrapolated scores from 
the two previous sets of 5-year estimates of the ACS were 
used.
Numerators are derived from all reported deaths in the 
United States with colorectal cancer identified as the under-
lying cause. Colorectal cancer mortality data are main-
tained by the National Center for Health Statistics and 
disseminated through the Surveillance Epidemiology and 
End Results program [14]. Cause of Death Recodes [15] 
is based on the International Classification of Diseases 
version 10 (ICD-10) for year of death from 1999 to 2010 
(ICD-10: C18–20, C26) and version 9 (ICD-9) for year of 
death from 1980 to 1998 (ICD-9: 153, 154.0–154.1, 159). 
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For each year and county, colorectal cancer deaths were 
categorized into NCI SES quintiles with the first quin-
tile being the lowest SES and the fifth quintile being the 
highest.
Denominator data from the bridged single race vintage 
2012 population estimates [16] were grouped into NCI SES 
quintiles. We calculated age-standardized rates for all colo-
rectal cancer deaths by dividing the numerators for each 
gender-specific quintile by its corresponding population 
estimate grouped by quintile and gender.
Analysis
We used the recommended sequence of steps to assess 
health disparities from the NCI Monograph [4]. The first 
step is to examine the underlying “raw” data, in this case 
mortality by subgroup. Age-adjusted mortality rates were 
calculated using SEER*Stat [17]. Significance of mortality 
trends from 1980 to 2010 was calculated using Joinpoint 
Regression Program 4.3 [18, 19]. The Joinpoint regression 
tests for statistically significant changes over time in the 
magnitude and direction of the change of the outcome (e.g., 
mortality rate and size of health disparities). Joinpoint 
breaks a time series into connected straight line segments 
by estimating the numbers and locations of join points. The 
change rate in the outcome is considered constant between 
two adjacent points, which is also known as the trend for 
this segment. Two types of measures are commonly used to 
measure the trend. For outcomes that are often assumed to 
be distributed linearly on a log scale, for example, mortal-
ity rates, the annual percent change (APC) is used. For out-
comes that do not require log-transformations, such as the 
health disparities measures that we examine in this study, 
a regression slope with interpretations that are similar to 
the one produced by simple linear regressions is used. In 
all Joinpoint regression analyses, the minimum and maxi-
mum numbers of join points were set to be zero and five, 
respectively, over the 1980–2012 period. Observations are 
assumed to be independent. Permutation tests were used to 
select the final model.
Using HD*Calc, we examined absolute and relative 
colorectal cancer mortality disparities by area-SES quin-
tiles. If the social group has a natural ordering, such as 
SES, the NCI monograph recommends using the Slope 
Index of Inequality (SII) or the Absolute Concentration 
Index (ACI) to measure absolute health disparity, and the 
Relative Index of Inequality (RII) or the Relative Con-
centration Index (RCI) to measure relative disparity. The 
Concentration index, whether measured on the absolute 
or relative scale, places an additional weight on the health 
of disadvantaged groups relative to advantaged groups 
and includes an inequality aversion parameter which can 
be adjusted [4]. For all measures, a value of zero means 
no disparities (except for the Kunst–Mackenback RII for 
which a value of 1 means no disparities), a positive value 
indicates a disparity in mortality in favor of low SES, and 
a negative value indicates a disparity in mortality in favor 
of high SES. The standard inequality aversion parameter, 
which equals 2, weights the health of the poorest individual 
by 2 and, thereafter, declines to 0 with increasing SES [20]. 
The aversion parameter can be used to specify how much 
weight is assigned to different parts of the socioeconomic 
distribution. The Indices of Inequality and the Concentra-
tion Indices are mathematically similar, so there is no rea-
son to compute both indices. Rather, different inequality 
aversion parameters for the ACI and the RCI were com-
pared to observe how disparity levels and trends would 
change as a result.
Another step concerns relative and absolute measure-
ment. Relative disparities are compared to a reference 
group and computed as a ratio. Absolute disparities are the 
difference between actual numbers. Importantly, these are 
different conceptual ways to measure disparities [21, 22]. 
Reporting just one can be misleading, and it is not uncom-
mon that using different measures may lead to different 
conclusions regarding the direction of disparity trends [4]. 
In short, scientific accuracy requires measuring both rela-
tive and absolute concepts before drawing conclusions [23, 
24]. Finally, the World Health Organization’s Commission 
on Social Determinants of Health, recommends reporting 
both absolute and relative measures for properly tracking 
health inequalities [25].
Results
Table 1 shows deaths from colorectal cancer for each SES 
quintile by gender in the United States from 1980 to 2010. 
The table suggests an association between SES and death 
from colorectal cancer.
Figure 1 presents the Joinpoint trend analysis of colorec-
tal cancer mortality rates by gender and SES quintile over 
time using annual age-adjusted rates for the United States. 
In 1980, higher SES is associated with a larger share of 
deaths, while at the end of the period, higher SES is associ-
ated with a smaller percentage of deaths. This association 
is exacerbated for males compared to females.
Average percent change was statistically significant for 
most trends, as Table 2 shows. In 1980, colorectal cancer 
mortality rates were highest in the highest area-SES quin-
tile, 80/100,000 and approximately 60/100,000 for men in 
the lowest quintile. By 2010, mortality rates for all men 
had dropped. Rates for men living in the higher SES areas 
dropped the most to about 32/100,000 (APC = −4.4, sig-
nificant); rates for low SES men dropped to approximately 
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Table 1  Death count, 
population, and age-adjusted 
mortality rate by county 
socioeconomic quintile and 
gender, US Mortality Data, 
1980–2010
a Mortality rates shown are per 100,000 person years
SES quintile Male Female
Death (n) Population (n) Mortality  ratea Death (n) Population (n) Mortality rate
SES 1 (low) 107,529 185,120,920 56.50 85,133 211,349,031 37.70
SES 2 101,790 178,931,705 56.35 80,572 204,583,695 37.30
SES 3 94,881 166,659,249 57.75 75,191 190,281,024 38.08
SES 4 90,447 168,916,368 55.06 71,586 190,651,488 36.61
SES 5 (high) 86,476 170,295,271 54.77 67,750 188,101,664 36.52
Fig. 1  Joinpoint analysis of 
US Colorectal Cancer Mortal-
ity. Rates by SES quintile and 
gender, 1980–2010
Table 2  Joinpoint trend results for the US Colorectal Cancer Mortality Rates by SES (SES) quintile and gender, 1980–2010
APC annual percent change
*APC is significantly different from zero at the 0.05 level
SES quintile Male Female
No. of trends Trend Start year End year APC No. of trends Trend start year End year APC
SES 1 (low) 2 1 1980 1996 −0.3* 2 1 1980 2001 −1.2*
2 1996 2010 −1.8* 2 2001 2010 −2.4*
SES 2 4 1 1980 1985 −0.2 2 1 1980 2000 −1.9*
2 1985 2002 −1.6* 2 2000 2010 −2.8*
3 2002 2005 −5.7* – – – –
4 2005 2010 −0.8 – – – –
SES 3 2 1 1980 1985 1.0 2 1 1980 1985 −0.5
2 1985 2010 −2.6* 2 1985 2010 −2.7*
SES 4 2 1 1980 2001 −2.2* 2 1 1980 1999 −2.4*
2 2001 2010 −3.8* 2 1999 2010 −3.4*
SES 5 (high) 3 1 1980 1987 −0.5 3 1 1980 1983 0.8
2 1987 2002 −3.1* 2 1983 2001 −2.9*
3 2002 2010 −4.4* 3 2001 2010 −4.2*
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46/100,000 (APC = −1.8, significant). This striking crosso-
ver in mortality rates occurred around 1993.
Figure  2 shows results from HD*Calc. The Absolute 
Concentration Index (ACI) shows disparities in mortal-
ity by SES status started out positive, indicating mortality 
favored the low SES groups, and fell to zero around the 
mid-1990s, after which disparities became negative, indi-
cating mortality favored the high SES group. Findings from 
the Relative Concentration Index (RCI) are consistent with 
the Absolute Concentration Index.
A key feature of the Extended Concentration Index 
is the inequality aversion parameter, which weights the 
health of the low-income quintile more than the high-
income quintile. We used the inequality aversion param-
eter to explore the extent to which CRC mortality is more 
concentrated in the lowest income quintile compared to 
the highest quintile. Figure  2 presents findings for ine-
quality aversion parameters set at 2 (the default), 4, 6, 
and 8. It is clear that larger inequality aversion parame-
ters reflect greater concentrations of CRC mortality in the 
poorest quintile up to a weight of 4. Aversion parameters 
greater than 4 showed no additional effect.
Fig. 2  Extended concentra-
tion indices for socioeconomic 
disparities in colorectal cancer 
mortality rates, entire US, 
1980–2010




Mortality from colorectal cancer dropped over the 30-year 
period from 1980 to 2010. At least for women, rates con-
sistently dropped since the 1950s [26]. However, not all 
SES groups have benefitted equally. Joinpoint regres-
sion analyses found larger declines in the APC for indi-
viduals living in higher SES areas. The changes in trends 
were more gradual among women compared to men. 
Trends were consistent for absolute and relative summary 
measures.
The concentration indices confirmed reversal of the 
area-SES gradient over the past 30 years, and showed that 
presently disparities are favoring higher SES groups. Com-
parisons of some other cancer sites have shown relative 
and absolute disparities moved in opposite directions, but 
both relative and absolute disparity trends were in the same 
direction for both men and women for colorectal cancer 
mortality.
We also took advantage of the fact that the Extended 
Concentration Index has an inequality aversion parameter 
allowing users to specify how much to weight health in 
lower SES groups. We found larger disparities and stronger 
reversals of the SES gradient over time for both men and 
women with increasing weights up to 4 but little change for 
greater levels of inequality aversion.
Advances in colorectal cancer screening and treatment
Medical procedures for colorectal cancer screening and 
treatment were developed starting in the 1980s. Screen-
ing techniques offer early detection, and treatment is more 
effective when cancer is detected early. Screening technol-
ogy for colorectal cancer was not widely used before 2000 
[27]. Surgery is the primary treatment modality for colo-
rectal cancer and, from 1987 until 1995, adjuvant therapy 
which improved colorectal cancer outcomes, was devel-
oped and widely adopted [28]. Continued discovery and 
accelerated adoption of chemotherapy and radiation ther-
apy between 1990 and 2010 contributed to still lower rates 
of mortality [29, 30]. However, these new procedures were 
not equally adopted by all SES groups [31–33].
Screening accounts for most of the early detection 
of colorectal cancer and, since 2000, colonoscopy has 
accounted for most of the increase in screening [34]. How-
ever, colonoscopy is expensive and higher SES adults 
are much more likely to report a recent colorectal cancer 
screening test [35]. In addition to early detection, colonos-
copy identifies adenomas which are removed during the 
colonoscopy procedure, thus preventing colorectal cancer 
[36]. In this way, increased colonoscopy in a population 
leads to both a reduction in colorectal cancer incidence and 
a shift to earlier stage diagnosis. Earlier detection improved 
survival after surgery, and survival after surgery improved 
even more after 1990, as surgery was accompanied by 
adjuvant chemotherapy. Because colonoscopy use is con-
centrated in high SES populations, it seems plausible that 
differences in screening are implicated in the reductions in 
colorectal cancer mortality associated with higher SES sta-
tus and with increasing SES disparities over time.
While expensive screening and treatment services are 
effective in reducing colorectal cancer mortality, their high 
cost makes it less likely that persons with low income or 
without health insurance will obtain them. As long as treat-
ment and, especially, screening for CRC are costly to con-
sumers in the United States, it seems likely that differen-
tial access will persist. The social gradient cannot be fully 
attributed to stage of disease, type of operation, specializa-
tion of surgery, or other clinical factors, because other stud-
ies have shown that the effect of SES on mortality persists 
after adjustment for these factors [37, 38]. It also is worth 
noting that another study documented faster declines in 
colorectal cancer mortality in higher SES areas since at 
least the 1950s, which would suggest that factors other than 
screening technology are also implicated in rising inequali-
ties [11]. Nevertheless, unless the high cost of colorectal 
cancer screening declines, we are skeptical that historical 
stages 3 and 4, which suggest a lessening of inequality, will 
occur [12].
Another approach to understanding the association 
between colorectal cancer mortality and SES is to posit 
low SES as an etiological factor underlying disparities in 
colorectal cancer mortality. From this point of view, higher 
colorectal cancer mortality associated with low SES is pre-
ventable and can be addressed. However, addressing low 
SES directly is too broad to be efficacious in reducing colo-
rectal cancer mortality rates. More promising are proven 
interventions that directly target barriers to screening and 
treatment.
Contribution of this study
Our contribution to the literature is an accurate and reliable 
description of the trend in disparities in colorectal cancer 
mortality from 1980 to 2010. We confirmed disparities in 
colorectal cancer associated with SES between 1980 and 
2010 using multiple summary disparity measures. Moreo-
ver, disparities are likely to continue to widen unless pro-
grams and policies are specifically directed to low SES 
populations to reverse the trend. Our findings on mortality 
are consistent with knowledge about screening and treat-
ment, and with theories concerning why SES gaps could 
occur when overall mortality declines [12–15]. However, 
the previous studies could not be reproduced or compared, 
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because different factors were included in the different SES 
quintiles. The NCI SES quintiles will be consistently meas-
ured using a standard set of factors.
The two free and open-source tools we used can improve 
estimates of disparities. The accuracy, reliability, and pre-
cision of measurement of summary trends in disparities 
depend on the quality and granularity of the data used for 
the calculations. The NCI SES quintiles are computed 
using a standard approach and provide more precise SES 
estimates over time, because each year is separately com-
puted in a consistent way. The mortality database with 
linked NCI county SES quintiles is available upon request 
in SEER*Stat (http://seer.cancer.gov/resources/specialized.
html). HD*Calc creates efficiencies in calculating tables 
and graphs for four absolute and seven relative indices of 
disparities. These tools can be used to update our findings 
as data become available.
Limitations
Due to changes in the collection of Census data in 1980, 
comparable SES quintiles cannot be constructed for earlier 
years. SES quintiles are available at the Census tract level, a 
smaller geographic unit than county, but mortality data for 
colorectal cancer are not available at the Census tract level 
due to confidentiality concerns. We caution readers not to 
interpret county level SES status as a proxy for individual 
SES status. National time series data on utilization for the 
full range of medical treatment for colorectal cancer with 
geographic indicators are not available. Finally, studies of 
shifts in cancer stage by SES have not been conducted.
Public health implications
Though the SES disparities that occurred with uptake of 
expensive new medical technologies may not be intended, 
it is not unexpected. Continued discovery and adoption of 
expensive screening and treatment for colorectal cancer 
[39, 40] suggest that this trend toward increasing disparities 
in colorectal cancer mortality may continue unless offset-
ting policies are put in place. New York [41] and Delaware 
[42] successfully established programs to promote equity 
in colorectal cancer screening. Delaware demonstrated that 
is it possible to achieve equity between African-Americans 
and whites in colon cancer screening, incidence, and mor-
tality rates, even though it cannot be ascertained whether 
the program was responsible for the reduction in racial 
disparities. However, it does seem clear that concerted 
and dedicated public health efforts across the cancer con-
trol continuum are needed to avoid disparities emerging 
alongside medical improvements [43]. To avoid medical 
interventions becoming causes of disparities in colorectal 
cancer mortality, colorectal cancer screening and treatment 
need to be equally accessible to all SES groups. This means 
developing and funding programs that specifically target 
groups that may not know about or are unable to afford 
CRC screening and treatment. Shifting from screening with 
expensive colonoscopy to screening with effective and low-
cost stool tests, such as the Fecal Immunochemical Test 
(FIT) or the stool DNA test, would make CRC screening 
more accessible [44]; however, currently, many providers 
charge co-pays for follow-up colonoscopy and this is a bar-
rier to colorectal cancer screening [45]. Some resistance to 
high prices for cancer drugs is occurring along with recog-
nition that the high cost of cancer treatment is leading to 
bankruptcies [46, 47].
Unless corrective measures are taken to promote and 
pay for routine screening, follow-up as needed, and timely 
affordable treatment in lower SES populations, medical ser-
vice uptake for colorectal cancer will continue to be higher 
among higher SES patients and disparities will continue to 
widen. The example of colorectal cancer is especially strik-
ing, because, before medical interventions, populations in 
lower SES areas experienced lower mortality. Our evidence 
shows a crossover in colorectal cancer mortality by SES 
that is consistent with the introduction of new technologies 
and adds plausibility to the impact of SES: as new technol-
ogy became available, screening, earlier stage diagnosis, 
and timely effective treatment for colorectal cancer were 
adopted earlier and used at higher rates in higher SES pop-
ulations. For lower SES populations to equally benefit from 
screening and treatment, programs and policies would need 
to be implemented that would bring screening, diagnostic 
and treatment services to low SES populations.
To see results, programs and policies need to be accu-
rately monitored over an extended period. Delaware mobi-
lized its health care community toward the goal of eliminat-
ing racial health disparities in colorectal cancer. Disparities 
in screening, incidence, advanced stage of disease, and 
mortality between Whites and African-Americans were 
eliminated between 2001 and 2009. Whether the inter-
vention was fully responsible for the elimination of racial 
disparities in colorectal cancer screening and mortality is 
unclear, because there was no control group. Future work 
should focus on better study designs to understand the 
mechanisms through which inequalities in colorectal can-
cer mortality are generated and sustained. Observational 
studies of colorectal cancer stage at diagnosis by SES to 
assess whether shifts in cancer stage by SES have occurred 
are important, and would be facilitated by the NCI SES 
Quintiles.
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